148 related articles for article (PubMed ID: 8045964)
1. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly.
Fløgstad AK; Halse J; Grass P; Abisch E; Djøseland O; Kutz K; Bodd E; Jervell J
J Clin Endocrinol Metab; 1994 Aug; 79(2):461-5. PubMed ID: 8045964
[TBL] [Abstract][Full Text] [Related]
2. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
3. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly.
Wagenaar AH; Harris AG; van der Lely AJ; Lamberts SW
Acta Endocrinol (Copenh); 1991 Dec; 125(6):637-42. PubMed ID: 1789059
[TBL] [Abstract][Full Text] [Related]
5. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide.
Li JK; Chow CC; Yeung VT; Mak TW; Ko GT; Swaminathan R; Chan JC; Cockram CS
Aust N Z J Med; 2000 Aug; 30(4):457-61. PubMed ID: 10985510
[TBL] [Abstract][Full Text] [Related]
8. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
9. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
Haraguchi K; Ohtaka M; Takazawa K; Endo T; Onaya T
Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
11. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
12. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
14. Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects.
Fredstorp L; Harris A; Haas G; Werner S
J Clin Endocrinol Metab; 1990 Nov; 71(5):1189-94. PubMed ID: 2229278
[TBL] [Abstract][Full Text] [Related]
15. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly.
de Herder WW; Uitterlinden P; van der Lely AJ; Hofland LJ; Lamberts SW
Eur J Endocrinol; 1995 Aug; 133(2):195-9. PubMed ID: 7544670
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump.
Giusti M; Cuttica CM; Cariola G; Valenti S; Sessarego P; Giordano G
Recenti Prog Med; 1995 May; 86(5):189-94. PubMed ID: 7604174
[TBL] [Abstract][Full Text] [Related]
18. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
19. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
[TBL] [Abstract][Full Text] [Related]
20. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
